Open AccessIschemia–reperfusion injury
Author(s) -
Naima Souidi,
Meaghan Stolk,
Martina Seifert
Publication year - 2013
Publication title -
current opinion in organ transplantation
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.832
H-Index - 51
eISSN - 1531-7013
pISSN - 1087-2418
DOI - 10.1097/mot.0b013e32835c2a05
Subject(s) - medicine , mesenchymal stem cell , paracrine signalling , reperfusion injury , microvesicles , inflammation , ischemia , transplantation , clinical trial , immune system , fibrosis , stromal cell , bioinformatics , pharmacology , immunology , microrna , cancer research , pathology , biology , receptor , biochemistry , gene
Organ transplantation and other major surgeries are impacted by ischemia-reperfusion injury (IRI). Mesenchymal stromal cells (MSCs) recently became an attractive alternative therapeutic tool to combat IRI. The present review highlights the effects of MSCs in the preclinical animal models of IRI and clinical trials, and explains their potential modes of action based on the pathophysiological IRI cascade.